IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Connecticut

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

 

Connecticut $ 13,847,706.16
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
Achillion Pharmaceuticals, Inc. ACH-2881 $ 166,432.50 $ 78,046.75
Achillion Pharmaceuticals, Inc. ACH-1625 $ 244,479.25  
Achillion Pharmaceuticals, Inc. ACH-2684 $ 244,479.25  
Achillion Pharmaceuticals, Inc. Elvucitabine $ 131,052.00 $ 113,427.25
Achillion Pharmaceuticals, Inc. ACH-2928 $ 244,479.25  
Achillion Pharmaceuticals, Inc. ACH-1095 $ 244,479.25  
Achillion Pharmaceuticals, Inc. ACH-702 $ 244,479.25  
Achillion Pharmaceutics, Inc. ACH-2892 $ 244,479.25  
AllerQuest, LLC Penicillin Minor Determinants (PMD)   $ 244,479.24
AllerQuest, LLC PrePen $ 51,598.50  
AMARIN PHARMACEUTICALS, INC. AMR101 $ 244,479.25  
Applied Spine Technologies, Inc Stabilimax Spine Stabilization System $ 244,479.24  
Artificial Cell Technologies Nanoparticulate Vaccine Against Respiratory Syncytial Virus $ 244,479.25  
Axerion Therapeutics Nogo receptor (NgR)protein therapy to treat chronic spinal cord injury   $ 244,479.25
Axerion Therapeutics Cellular Prion Protein (PrP) as a treatment for Alzheimer's Disease   $ 122,818.50
Beta Pharma, Inc Icotinib, a novel drug for the treatment of EGFR-mutated cancer diseases. $ 87,192.09 $ 157,287.16
Biodel Inc Smart Basal $ 244,479.25  
Biodel, Inc VIAject $ 244,479.25  
Biodel, Inc. Improved Glargine $ 244,479.25  
Biodel, Inc. Glucagon $ 244,479.25  
Biodel, Inc. VIAtab $ 244,479.25  
Biomedisyn Corporation Huperzine for the Treatment of Schizophrenia $ 21,405.80 $ 137,070.98
BioRelix, Inc. Novel riboswitch-targeting treatments for multi-drug resistanr and hypervirulent bacteria $ 244,479.24  
Biowave Corporation Prescription Peripheral Neuromodulation Pain System $ 48,055.00 $ 95,700.00
Brain Tunnelgenix Technologies Corp Discovery of the Brain Temperature Tunnel ( BTT) and the world's first non-invasive brain temperature monitoring device $ 244,479.24  
Cara Therapeutics Inc Development of A Novel Analgesic, CR845 $ 244,479.24  
CAS Medical Systems Inc Non-Invasive Cerebral/Tissue Oximetry $ 244,479.25  
Cheminpharma LLC MEK Inhibitor for Treatment of Cancer $ 59,362.50  
Cytogel Pharma, LLC Cyt-1010 $ 244,479.24  
CyVek, Inc (FKA CyVek, LLC) CyVek: Enabling Proteomics $ 21,281.00 $ 223,198.25
Genomas, Inc PhyzioType System:Improve Treatment Outcome of Drugs for Mental Illness & Heart Disease $ 156,399.00 $ 88,080.24
HistoRx Inc AQUA technology Dianostics Enabling Better Treatment Decision $ 244,479.25  
Ikonisys Inc OncoFISH cervical test $ 244,479.24  
IVFonline.com DBA Zenith Biotech, LLC Develop and make liver biomatrix for extended hepatocyte functionality for drug discovery $ 81,500.00 $ 63,000.00
IVFonline.com DBA Zenith Biotech, LLC Novel Predictive Model for Hepatocytes Toxicity in Preclinical Drug Screening $ 95,000.00 $ 107,500.00
IVFonline.com DBA Zenith Biotech, LLC. Scalable Human Neural Stem Cells for High Throughput Screening $ 122,500.00 $ 118,000.00
Kolltan Pharmaceuticals, Inc RTK Project No. 5 $ 244,479.25  
Kolltan Pharmaceuticals, Inc RTK Project No.4 $ 244,479.25  
Kolltan Pharmaceuticals, Inc RTK Project No.3 $ 244,479.25  
Kolltan Pharmaceuticals, Inc. RTK Project No. 1 $ 244,479.25  
Kolltan Pharmaceuticals, Inc. RTK Project No. 2 $ 244,479.25  
Kolltan Pharmaceuticals, Inc. RTK Project No. 6 $ 244,479.25  
Kotinos Pharmaceuticals Inc Development of Tigapotide (PCK3145) as novel therapy for prostate cancer $ 196,017.00 $ 48,462.24
Marinus Pharmaceuticals Inc. Ganaxolone for Adjunctive Treatment of Partial Onset Seizures $ 244,479.25  
Marinus Pharmaceuticals Inc. Ganaxolone for Treatment of Posttraumatic Stress Disorder (PTSD) $ 244,479.25  
MEDADHERENCE LLC DIABETES REMOTE MANAGEMENT SYSTEM $ 244,479.25  
Molecular Neuroimaging LLC Biomarkers for the Diagnosis of Parkinson's Disease $ 222,854.00 $ 21,625.25
Molecular Neuroimaging LLC Biomarkers for the Diagnosis of Alzheimer Disease $ 202,974.50 $ 41,504.75
Myometrics, LLC A small molecule agonist for enhancing alvelolar bone regeneration in toothextraction $ 10,043.50 $ 1,230.50
Optherion, Inc rhCFHp - Recombinant Human Factor H $ 244,479.24  
Protein Sciences Corporation FluBlok $ 244,479.25  
Protein Sciences Corporation PanBlok $ 244,479.25  
RIB-X PHARMACEUTICALS INC RX-04 Completely New Antibiotics to Treat Multi-drug Resistant Infections $ 244,479.25  
RIB-X PHARMACEUTICALS, INC. Delafloxacin: a broad spectrum antibiotic for the treatment of multi-drug resistant infections $ 244,479.25  
RIB-X PHARMACEUTICALS, INC. RX-02: Enhanced Marcrolides for Treating Drug-Resistant Community Infections $ 244,479.25  
RIB-X PHARMACEUTICALS, INC. Radezolid: A Novel Oxazolidinone Antibiotic for Resistant Gram-positive Infections $ 244,479.25  
Sibtech Inc Guiding Cancer Therapy by imaging VEGF Receptors $ 244,479.25  
SurgiQuest, Inc. AirSeal ® Trocar & Cannula System $ 244,479.25  
The Bronx Project Inc The Bronx Project $ 26,739.00 $ 217,740.25
The Institutes for Pharmaceutical Discovery LLC Arginase Inhibitor Program $ 244,479.24  
The Institutes for Pharmaceutical Discovery LLV Urinary Peptide Assay   $ 244,479.24
Page Last Reviewed or Updated: 09-Apr-2014